Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.
PURPOSE Patients with metastatic castration-resistant prostate cancer (mCRPC) and advanced breast cancer (aBC) have poor outcomes with standard treatments. We report phase 1 results from the STESIDES (NCT03878823) study of ODM-209, an oral selective CYP11A1 inhibitor that blocks all synthesis of steroid hormones. MET...